Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
AVN944 Shows Potent Antiproliferative Activity in Human Endothelial Cells
May 1st, 2007
Avalon Pharmaceuticals, Inc. (NASDAQ:AVRX), today described the potent antiproliferative activity of AVN944 in human endothelial cells (HUVEC), and showed that the compound prevents blood vessel formation in a mouse model. The newly elucidated antiangiogenic properties of the compound were examined in a study poster entitled, "Antiangiogenic Properties of AVN944, A Potent Inhibitor of IMPDH," presented at the American Association for Cancer Research Annual Meeting held April 14-18, 2007, in Los Angeles. "Results of this study provide new insight into the mechanism of action of AVN944," stated Zoe Weaver, Ph.D., staff scientist at Avalon and lead investigator in the...
Source: Cancer Weekly (2007-05-01)
|
